Trends in antimicrobial resistance among clinical isolates of the Bacteroides fragilis group from 1992 to 1997 in Montreal, Canada

被引：22
|
作者：
Labbé, AC [1 ]
Bourgault, AM [1 ]
Vincelette, J [1 ]
Turgeon, PL [1 ]
Lamothe, F [1 ]
机构：
[1] CHU Montreal, Dept Microbiol Med & Infectiol, Montreal, PQ H2X 3J4, Canada
来源：
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 1999年 / 43卷 / 10期
关键词：
D O I：
10.1128/AAC.43.10.2517
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
The objective of the present study was to analyze the susceptibility profiles of 911 clinical strains of the Bacteroides fragilis group isolated from 1992 to 1997 in our institution in order to monitor susceptibility changes over time. Whereas the rates of resistance to metronidazole, imipenem, piperacillin-tazobactam, ticarcillin-clavulanic acid, penicillin, piperacillin, and cefoxitin remained essentially unchanged, there was a significant increase in the rates of resistance to clindamycin, which rose from 8.2% in 1992 to 19.7% in 1997 (P < 0.0004).
引用
收藏
页码：2517 / 2519
页数：3
相关论文
共 50 条
  • [31] Resistance Trends of Bacteroides fragilis Group Over an 8-Year Period, 1997-2004, in Korea
    Roh, Kyoung Ho
    Kim, Sinyoung
    Kim, Chang-Ki
    Yum, Jong Hwa
    Kim, Myung Sook
    Yong, Dongeun
    Lee, Kyungwon
    Kim, June Myung
    Chong, Yunsop
    KOREAN JOURNAL OF LABORATORY MEDICINE, 2009, 29 (04): : 293 - 298
  • [32] Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain
    Betriu, Carmen
    Culebras, Esther
    Gomez, Maria
    Lopez, Fatima
    Rodriguez-Avial, Iciar
    Picazo, Juan J.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2008, 52 (07) : 2686 - 2690
  • [33] Time for Some Group Therapy: Update on Identification, Antimicrobial Resistance, Taxonomy, and Clinical Significance of the Bacteroides fragilis Group
    Jean, Sophonie
    Wallace, Miranda J.
    Dantas, Gautam
    Burnham, Carey-Ann D.
    JOURNAL OF CLINICAL MICROBIOLOGY, 2022, 60 (09)
  • [34] RECOVERY OF BACTEROIDES-FRAGILIS GROUP FROM CLINICAL SPECIMENS FOLLOWING ANTIMICROBIAL THERAPY
    BROOK, I
    FRAZIER, EH
    CANADIAN JOURNAL OF MICROBIOLOGY, 1992, 38 (03) : 226 - 229
  • [35] Recent Trends in Antimicrobial Resistance among Anaerobic Clinical Isolates
    Reissier, Sophie
    Penven, Malo
    Guerin, Francois
    Cattoir, Vincent
    MICROORGANISMS, 2023, 11 (06)
  • [36] Antimicrobial activity of moxifloxacin against trovafloxacin susceptible and resistent isolates of the bacteroides fragilis group
    Rosenblatt, JE
    Gustafson, D
    Sloan, L
    Steckelberg, J
    CLINICAL INFECTIOUS DISEASES, 2000, 31 (01) : 226 - 226
  • [37] ANTIMICROBIAL SUSCEPTIBILITY OF RELATIVELY INFREQUENT ISOLATES OF THE BACTEROIDES-FRAGILIS GROUP - BACTEROIDES-UNIFORMIS, BACTEROIDES-CACCAE, AND BACTEROIDES-EGGERTHII
    ALDRIDGE, KE
    CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 1993, 54 (02): : 208 - 213
  • [38] Identification of antimicrobial resistance genes in multidrug-resistant clinical Bacteroides fragilis isolates by whole genome shotgun sequencing
    Sydenham, Thomas Vognbjerg
    Soki, Jozsef
    Hasman, Henrik
    Wang, Mikala
    Justesen, Ulrik Stenz
    ANAEROBE, 2015, 31 : 59 - 64
  • [39] National survey on the susceptibility of Bacteroides fragilis group:: Report and analysis of trends in the united states from 1997 to 2004
    Snydman, D. R.
    Jacobus, N. V.
    McDermott, L. A.
    Ruthazer, R.
    Golan, Y.
    Goldstein, E. J. C.
    Finegold, S. M.
    Harrell, L. J.
    Hecht, D. W.
    Jenkins, S. G.
    Pierson, C.
    Venezia, R.
    Yu, V.
    Rihs, J.
    Gorbach, S. L.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2007, 51 (05) : 1649 - 1655
  • [40] Detection of enterotoxin and protease genes among Hungarian clinical Bacteroides fragilis isolates
    Sarvari, Karoly Peter
    Soki, Jozsef
    Ivan, Miklos
    Miszti, Cecilia
    Latkoczy, Krisztina
    Melegh, Szilvia Zsoka
    Urban, Edit
    ANAEROBE, 2017, 48 : 98 - 102
12345